0.24
-0.0335(-12.41%)
Currency In USD
| Previous Close | 0.27 |
| Open | 0.44 |
| Day High | 0.45 |
| Day Low | 0.21 |
| 52-Week High | 4.71 |
| 52-Week Low | 0.21 |
| Volume | 182.91M |
| Average Volume | 752,427 |
| Market Cap | 1.48M |
| PE | -0.07 |
| EPS | -3.3 |
| Moving Average 50 Days | 0.39 |
| Moving Average 200 Days | 1.12 |
| Change | -0.03 |
If you invested $1000 in Shuttle Pharmaceuticals Holdings, Inc. (SHPH) since IPO date, it would be worth $0.77 as of May 10, 2025 at a share price of $0.237. Whereas If you bought $1000 worth of Shuttle Pharmaceuticals Holdings, Inc. (SHPH) shares 2 years ago, it would be worth $25.48 as of May 10, 2025 at a share price of $0.237.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial
GlobeNewswire Inc.
May 08, 2025 8:01 PM GMT
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for canc
Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
GlobeNewswire Inc.
Apr 21, 2025 8:15 PM GMT
Company to conduct 1x1 meetings on April 24, 2025GAITHERSBURG, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceut
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
GlobeNewswire Inc.
Apr 10, 2025 8:01 PM GMT
Filing provisional patent application with the USPTO entitled “PSMA-Targeted PARP Inhibitor conjugates for Precision Cancer Therapy” key to advancement of Diagnostic and Therapeutic programs Dr. Alan Kozikowski, internationally acclaimed pioneer in t